Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum

Journal of Clinical Microbiology

Volumn 38, Issue 2, 2000, Pages 656-661

  Woods, Gail L ^a   Bergmann, John S ^a   Witebsky, Frank G ^b   Fahle, Gary A ^b   Boulet, Betty ^c   Plaunt, Marianne ^d   Brown, Barbara A ^e   Wallace Jr , Richard J ^e   Wanger, Audrey ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Statprobe   (United States)

^e UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; SULFAMETHOXAZOLE;

ACCURACY; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STRAIN DIFFERENCE;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; UNCULTURED ACTINOMYCETE;

EID: 0033950611     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.2.656-661.2000     Document Type: Article

References (21)

1. Band, J. D., J. I. Ward, D. W. Fraser, N. J. Peterson, V. A. Silcox, R. C. Good, P. R. Ostroy, and J. Kennedy. 1982. Peritonitis due to a Mycobacterium chelonei-like organisms associated with intermittent chronic peritoneal dialysis. J. Infect. Dis. 145:9-17.
2. Biehle, J. R., S. J. Cavalieri, M. A. Saubolle, and L. J. Getsinger. 1995. Evaluation of Etest for susceptibility testing of rapidly growing mycobacteria. J. Clin. Microbiol. 33:1760-1764.
3. Brown, B. A., J. M. Swenson, and R. J. Wallace, Jr. 1994. Broth microdilution MIC test for rapidly growing mycobacteria, p. 5.11.1. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
4. Brown, B. A., R. J. Wallace, Jr., G. Onyi, V. DeRosas, and R. J. Wallace III. 1992. Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonae-like organisms. Antimicrob. Agents Chemother. 36:180-184.
5. Dalovisio, J. R., G. A. Pankey, R. J. Wallace, Jr., and D. B. Jones. 1981. Clinical usefulness of amikacin and doxycycline in the treatment of human infection of Mycobacterium fortuitum and Mycobacterium chelonei. Rev. Infect. Dis. 3:1068-1074.
6. Griffith, D. E., W. M. Girard, and R. J. Wallace, Jr. 1993. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Am. Rev. Respir. Dis. 147:1271-1278.
7. Hoffner, S. E., L. Klintz, B. Olsson-Liljequist, and A. Bolmstrom. 1944. Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum. J. Clin. Microbiol. 32:1846-1849.
8. Ingram, C. W., D. C. Tanner, D. T. Durack, G. W. Kernodle, Jr., and G. R. Corey. 1993. Disseminated infection with rapidly growing mycobacteria. Clin. Infect. Dis. 16:463-471.
9. Koontz, F. P., M. E. Erwin, M. S. Barrett, and R. N. Jones. 1994. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates. Diagn. Microbiol. Infect. Dis. 19:183-186.
10. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing; eighth informational supplement. M100-S8. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Prammananan, T., P. Sander, B. A. Brown, K. Frischkorn, G. O. Onyi, Y. Zhang, E. C. Bottger, and R. J. Wallace, Jr. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis. 177:1573-1581.
12. Steingrube, V. A., J. L. Gibson, B. A. Brown, Y. Zhang, R. W. Wilson, M. Rajagopalan, and R. J. Wallace, Jr. 1995. PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly glowing mycobacteria. J. Clin. Microbiol. 33:149-153.
13. Swenson, J. M., R. J. Wallace, Jr., V. A. Silcox, and C. Thornsberry. 1985. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob. Agents Chemother. 28:807-811.
14. Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution. Antimicrob. Agents Chemother. 22:186-192.
15. Wallace, R. J., Jr., A. Meier, B. A. Brown, Y. Zhang, P. Sander, G. O. Onyi, and E. C. Bottger. 1996. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. 40:1676-1681.
16. Wallace, R. J., Jr., B. A. Brown, and G. O. Onyi. 1992. Skin, soft tissue, and bone infections due to Mycobacteria chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J. Infect. Dis. 166:405-412.
17. Wallace, R. J., Jr., B. A. Brown, and G. O. Onyi. 1991. Susceptibilities of Mycobacterium fortuitum biovar fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob. Agents Chemother. 35:773-775.
18. Wallace, R. J., Jr., J. L. Cook, J. Glassroth, D. E. Griffith, K. N. Olivier, and F. Gordin. 1997. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. American Thoracic Society Statement. Am. J. Respir. Crit. Care Med. 156:S1-S25.
19. Wallace, R. J., Jr., V. A. Silcox, M. Tsukamura, B. A. Brown, J. O. Kilburn, W. R. Butler, and G. Onyi. 1993. Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism. J. Clin. Microbiol. 31:3231-3239.
20. Wallace, R. J., Jr., J. M. Swenson, V. A. Silcox, and M. G. Bullen. 1985. Treatment of non-pulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei: based on in vitro susceptibilities. J. Infect. Dis. 152:500-514.
21. Woods, G. L., J. S. Bergmann, F. G. Witebsky, G. A. Fahle, A. Wanger, B. Boulet, M. Plaunt, B. A. Brown, and R. J. Wallace, Jr. 1999. Multisite reproducibility of broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J. Clin. Microbiol. 37:1676-1682.